Angiomax is a drug owned by Sandoz Inc. It is protected by 6 US drug patents filed in 2013. Out of these, 4 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 27, 2029. Details of Angiomax's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US7582727 (Pediatric) | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jan, 2029
(4 years from now) | Active |
|
US7598343 (Pediatric) | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jan, 2029
(4 years from now) | Active |
| US7582727 | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jul, 2028
(3 years from now) | Active |
| US7598343 | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jul, 2028
(3 years from now) | Active |
|
US5196404 (Pediatric) | Inhibitors of thrombin |
Jun, 2015
(9 years ago) |
Expired
|
| US5196404 | Inhibitors of thrombin |
Dec, 2014
(10 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Angiomax's patents.
Latest Legal Activities on Angiomax's Patents
Given below is the list of recent legal activities going on the following patents of Angiomax.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 24 Mar, 2021 | US7598343 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Feb, 2021 | US7582727 |
| Recordation of Patent Grant Mailed Critical | 06 Oct, 2009 | US7598343 (Litigated) |
| Patent Issue Date Used in PTA Calculation Critical | 06 Oct, 2009 | US7598343 (Litigated) |
| Issue Notification Mailed Critical | 16 Sep, 2009 | US7598343 (Litigated) |
| Sequence Moved to Public Database | 15 Sep, 2009 | US7582727 |
| Dispatch to FDC | 08 Sep, 2009 | US7598343 (Litigated) |
| Sequence Forwarded to Pubs on Tape | 04 Sep, 2009 | US7598343 (Litigated) |
| Patent Issue Date Used in PTA Calculation Critical | 01 Sep, 2009 | US7582727 |
| Recordation of Patent Grant Mailed Critical | 01 Sep, 2009 | US7582727 |
US patents provide insights into the exclusivity only within the United States, but Angiomax is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Angiomax's family patents as well as insights into ongoing legal events on those patents.
Angiomax's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Angiomax's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 27, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Angiomax Generic API suppliers:
Bivalirudin is the generic name for the brand Angiomax. 10 different companies have already filed for the generic of Angiomax, with Hospira having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Angiomax's generic
How can I launch a generic of Angiomax before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Angiomax's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Angiomax's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Angiomax -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 250 mg/vial | 01 Sep, 2009 | 1 | 27 Jul, 2028 | Extinguished |
Alternative Brands for Angiomax
Angiomax which is used for preventing blood clot formation., has several other brand drugs using the same active ingredient (Bivalirudin). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Maia Pharms Inc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Bivalirudin, Angiomax's active ingredient. Check the complete list of approved generic manufacturers for Angiomax
About Angiomax
Angiomax is a drug owned by Sandoz Inc. It is used for preventing blood clot formation. Angiomax uses Bivalirudin as an active ingredient. Angiomax was launched by Sandoz in 2000.
Approval Date:
Angiomax was approved by FDA for market use on 15 December, 2000.
Active Ingredient:
Angiomax uses Bivalirudin as the active ingredient. Check out other Drugs and Companies using Bivalirudin ingredient
Treatment:
Angiomax is used for preventing blood clot formation.
Dosage:
Angiomax is available in injectable form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 250MG/VIAL | INJECTABLE | Prescription | INTRAVENOUS |